Results 181 to 190 of about 89,996 (262)

Effects of Zaozhu Yinchen Decoction on a Rat Model of Nonalcoholic Steatohepatitis via Regulation of Myeloid-Derived Suppressor Cells. [PDF]

Hepat Med
Zhang W, Wang Y, Liu Y, Zheng X, Wang T, Kwan X, Liu R, Liu Q, Zhuang H, Liang H, Chen S.   +10 more
europepmc   +1 more source

Real‐World Use of Semaglutide for Weight Management: Dose Titration, Discontinuation Patterns and Weight Changes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim In December 2022, semaglutide injections for weight management were marketed in Denmark. Pre‐marketing trials documented high efficacy when adherence to the treatment and the recommended dose titration schedule was followed. This study aimed to describe real‐world use of semaglutide, including dose titration, discontinuation patterns and ...
Mie Dyberg Skandov, Katrine McLain Christensen, Dagmar Abelone Dalin, Janne Unkerskov, Andreas Brønden, Marie Lund, Mikkel Bring Christensen, Kristian Karstoft   +7 more
wiley   +1 more source

Comparison of patients with HCC with and without MASLD after surgical resection. [PDF]

JHEP Rep
Ho CJ, Lei HJ, Ho CT, Chau GY, Chou SC, Chia-Hui Tan E, Lee PC, Huang YH, Yang YY, Huo TI, Hou MC, Wu JC, Su CW.   +12 more
europepmc   +1 more source

Ironing out Steatohepatitis

Annals of Hepatology, 2017
openaire   +5 more sources

GLP-1 Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Bridging Hepatic and Cardiovascular Outcomes. [PDF]

Chronic Dis Transl Med
Amorim Moreira Alves G, Teranishi M, Majumdar R, Khan F, Dodeja M, Teixeira de Castro Gonçalves Ortega AC, Acerboni M, Perera Molligoda Arachchige AS, James F.   +8 more
europepmc   +1 more source

Body Composition Remodelling During GLP‐1‐Based Therapy: A Systematic Review and Meta‐Analysis Using a Hierarchical Physiological Framework

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Body composition changes during glucagon‐like peptide‐1 (GLP‐1)‐based therapy remain incompletely characterized, particularly regarding their effects on adiposity, muscle quantity, and muscle quality. We conducted a systematic review and meta‐analysis using a predefined physiological framework to evaluate body composition ...
Maria Luizza Lopes Menezes, Maria Eduarda Güntzel Chiappa, Rodrigo Fuentes Kloss, Marcelo Tuesta, Paula Santos, Alberto Souza Sá Filho, Gaspar R. Chiappa   +6 more
wiley   +1 more source

Effect of weight reduction on liver volume in living liver donors with steatosis: a retrospective cohort study. [PDF]

Ann Surg Treat Res
Hong K, Lee KW, Hong SY, Lee S, Choi HH, Kim J, Lee J, Kim JY, Lee JM, Hong SK, Choi Y.   +10 more
europepmc   +1 more source

Therapies for Cardiovascular‐Kidney‐Liver‐Metabolic Syndrome: Reappraisal of Fibrates

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Cardiovascular disease, chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM), obesity and metabolic dysfunction‐associated steatohepatitis (MASH) frequently coexist and share overlapping pathophysiology, forming the proposed cardiovascular‐kidney‐liver‐metabolic (CKLM) syndrome.
Virginia Anagnostopoulou, Christoforos K. Travlos, Lucas Lage Marinho, Thomas A. Mavrakanas, João Pedro Ferreira, Abhinav Sharma   +5 more
wiley   +1 more source

Understanding the Humanistic Burden of Metabolic Dysfunction-Associated Steatohepatitis Liver Disease in the US Population: Age/Sex Stratified Analysis of Morbidity and Mortality. [PDF]

Pharmacoecon Open
Briggs AH, Lin Z, Aggio D, Wittrup-Jensen V, Augustin S, Schneider J, Lloyd A.   +6 more
europepmc   +1 more source

Efficacy of Luseogliflozin Added to Semaglutide in Patients With Metabolic Dysfunction‐Associated Steatohepatitis and Type 2 Diabetes Mellitus: A Randomised, Open‐Label Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Type 2 diabetes drives the progression of metabolic dysfunction‐associated steatohepatitis (MASH). We evaluated whether antidiabetic therapy, specifically adding sodium–glucose cotransporter 2 (SGLT2) inhibitor to a glucagon‐like peptide‐1 receptor agonist (GLP‐1RA), improves liver histology in adults with biopsy‐proven MASH and type 2 ...
Teruki Miyake, Osamu Yoshida, Shinya Furukawa, Masashi Hirooka, Masanori Abe, Yoshio Tokumoto, Ayumi Kanamoto, Takao Watanabe, Ryo Yano, Yuki Okazaki, Atsushi Yukimoto, Yoshiko Nakamura, Eiji Takeshita, Teru Kumagi, Yoichi Hiasa   +14 more
wiley   +1 more source